Financing: €46m for Swedish oncology hopeful

Financing: €46m for Swedish oncology hopeful

Aprea will use the money to further the clinical development of its lead drug, a promising anticancer agent. APR-246 targets and reactivates the tumour suppressor protein p53, reviving its many mechanisms of anticancer function. About half of all

(Visited 1 times, 1 visits today)
12
Like
Save

Comments

Comments are disabled for this post.